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RESUMO 
O objetivo deste trabalho é demonstrar a aplicabilidade da Cromatografia Líquida de Alta Eficiência na quan-
tificação do Di(2-etilhexil ftalato) (DEHP) liberado pela linha de Policloreto de vinila  (PVC) no sangue cir-
culante durante o procedimento de hemodiálise. Como a proposta não é a validação do método foram coleta-
das amostras de sangue de cinco pacientes voluntários e de três voluntários saudáveis e os plasmas foram 
isolados, preparados e analisados. A concentração média de DEHP no sangue no plasma dos pacientes foi 
0.19±0.12 mg/kg de massa corpórea, enquanto que no plasma dos voluntários saudáveis foi 0.003±0.002 
µg/kg de massa corpórea. Os resultados mostraram que o método apresentado é uma alternativa para a de-
terminação de DEPH no sangue e que poderá auxiliar na busca por outros materiais para aplicação em equi-
pamentos de circulação extracorpórea. O estudo foi realizado de acordo com os padrões nacionais e interna-
cionais de ética em pesquisa envolvendo seres humanos (CEP PUCPR Prot. n.5802). 
Palavras-chave: Diálise renal, Toxicidade crônica, DEHP. 
ABSTRACT 
The objective of the work is to demonstrate the applicability of the High-Performance Liquid Chromatog-
raphy (HPLC) on the quantification of the Di(2-ethylhexyl phthalate) (DEHP) released from the Polyvinyl 
Chloride (PVC) line into the circulating blood during the hemodialysis procedure. As the proposal is not to 
validate the method, blood samples from five patients and three healthy volunteers were collected, and the 
plasmas were isolated, prepared and analyzed. The average concentration of DEHP in the patient's plasma 
was 0.19±0.12 mg/kg of body mass, while in the plasma of the healthy volunteers was 0.003±0.002 µg/kg of 
body mass. The results showed that the method presented is an alternative to quantify the DEHP in the blood 
and could assist in the search for alternative materials to apply to extracorporeal circulation equipment. The 
study was performed according to the national and international standards of ethics in research involving 
human beings (CEP PUCPR Prot. n.5802). 
Keywords: Renal dialysis, Chronic toxicity, DEHP. 
1. INTRODUCTION 
 The Chronic Kidney Disease (CKD) is characterized by a gradual loss of kidney function resulting in 
increasing of the metabolites concentration in plasma from the protein metabolism. Such a situation causes an 
increase in urea and creatinine that obligates the patient to undergo long treatment, often leading to chronic 
complications [1]. The treatments normally used are hemodialysis, peritoneal dialysis and renal transplanta-
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tion [2]. 
Hemodialysis therapy is carried out through the decontamination of blood during extracorporeal circu-
lation. A pump drives the blood from the patient's body through a dialyzer and returns it to the patient free of 
toxic substances [3] [4]. In some countries, like Brazil, for now, the extracorporeal circuits can be reused, up 
to twenty times, on the same patient with the approval of the National Health Surveillance Agency (RDC 
154/2004 ANVISA). Although reuse is a normal practice in some hemodialysis centers, it is a controversial 
subject for many researchers and health professionals, since some studies have shown that reuse has in-
creased the number of hospitalization and mortality [5] [6] [7]. 
The extracorporeal circuits are made of Polyvinyl Chloride (PVC), one of the most widely used poly-
mers in the medical devices industry [8]. The polymeric chain of PVC is formed from the reaction between 
vinyl chloride monomers, which polar covalent bonds provide stiffness to the polymer. The plasticizers are 
added to give flexibility, facilitating the processing and use of the polymer [9] [10]. 
A quarter of the plasticizers used in the industry corresponds to the di (2-ethylhexyl phthalate) 
(DEHP) which is present in PVC in up to 40% by weight, corresponding to about 10 g of plasticizer in a 
blood bag [11].The mass diffusion of DEHP from the extracorporeal circuit to the blood depends on several 
factors including temperature, storage time, blood flow, the percentage of DEHP in the product, and the lipo-
philic nature of the blood [12]. The DEHP, Figure 1, has a molecular weight of 390.56 g/mol [13] and a mol-
ecule with low molecular weight (<1000 g/mol) have low resistance to cross the membrane of the dialyzer 
having the concentration gradient as driving force [14]. Also due to its chemical structure and its lipid solu-
bility, DEHP can be easily absorbed by the body [11] [15]. The target organs of DEHP toxicity are kidneys, 
liver and, in particular, the testicles. Hepatomegaly is related to the DEHP presence as well as platelet aggre-





Figura 1: Chemical structure of Di-(2-ethylhexyl) phthalate [17]. 
Most studies on the effects of DEHP on the body, however, were conducted on animals. Effects in 
male animals include a change in zinc concentration, infertility, and testicular atrophy. The Food and Drug 
Administration (FDA) that has reported analogous symptoms in male patients undergoing dialysis, strongly 
suggesting the similarity between the reactions observed in animals with those observed in humans [18]. Alt-
hough DEHP contamination is common, most of the works in the literature discuss the contamination associ-
ated with industrialized products (pipes and household items) and PVC manufacturing industries. Very few 
studies are related to the contamination of patients with CKD since most countries have already changed he-
modialysis PVC lines by the silicone ones. Brazil, however, continues to use and reuse the PVC lines.  
Various analytical methods are available for determination of DEHP in biological systems. Among 
them, the method considered more accurate, fast and economical is the High-Performance Liquid Chroma-
tography (HPLC). However, the samples are not easily prepared [19], and the few studies using it do not 
show a clear method able to be reproduced. Therefore, the values found in the literature can hardly be corre-
lated with each other, leading to controversy about the real cumulative effect of DEHP on the body and its 
clinical implications. 
Take into account the importance to quantify the DEHP in the blood to evaluate its systemic effects, 
the aim of this study is to present a clear procedure to prepare blood samples for HPLC to quantify the DEHP 
released in the blood of patients during hemodialysis procedures. Also, the purpose is to demonstrate the fea-
sibility of the method. For that, the method of samples preparation, DEHP detection and the mathematical 
approach are exposed. 
2. MATERIALS AND METHOD 
A prospective primary study was conducted. During the hemodialysis session were collected blood aliquots 
of 20 ml of five volunteers patients selected by the inclusion criteria: male; above eighteen years of age; di-
agnosed with CKD; performing hemodialysis therapy from twelve months to twelve years; and hemodialysis 
sessions of four hours, three times a week.  
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The exclusion criteria were: diagnosed with Acquired Immune Deficiency Syndrome (AIDS) and/or 
hepatitis. For the control group was selected three volunteers considered healthy according to the inclusion 
criteria: male, over eighteen years with no diagnosed diseases. Because they are considered healthy, there 
were no exclusion criteria for the control group. 
All volunteer patients used the hemodialysis circuit produced by the same manufacturer, including the 
polyether sulfone dialyzers Nipro
TM
, model PES-210DL, with a surface area of 2.1 m
2
, convective clearance 
and ultrafiltration coefficient of 21 ml/h/mmHg. All patients underwent the same hemodialysis technique. 
Were chosen three sessions for each patient volunteer where 10 ml of blood were collected from a peripheral 
venous, fifteen minutes from the start of the hemodialysis. The aliquot was stored in a heparin tube and im-
mediately centrifuged in an Eppendorf Centrifuge (Model 5702), at 4400 xg for 10 min to separate the plas-
ma. The plasma was transferred to a glass test tube and frozen to -80 
o
C to prevent DEHP degradation [20], 
remaining stored until the time of its analysis in the HPLC. 
Fifteen minutes before the end of the session a second 10 ml aliquot of blood was collected, also from 
a peripheral venous. The same procedure for separation of plasma and storage was carried out. The proce-
dures were repeated for the number of reuse of the extracorporeal circuit. The reprocessing of the hemodialy-
sis circuit was performed according to the institution's protocol and by a qualified professional. For the 
healthy volunteers, it was taken only 10 ml of blood on one occasion. Table 1 shows the hemodialysis pa-
rameters for the volunteer patients. 
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8,000 350 4 years and 9 months 
*Patient candidate for renal transplant. Reuse number 0 means first use. 
For the purpose of the study, it was analyzed only the DEHP accumulated in plasma because only a 
small portion of the plasticizer (between 5% to 10%) is associated with the red blood cells [21].  
The HPLC analysis was performed by a Shimadzu
TM
 UV-VIS System LC-20 with the following 
specifications: column C18 9 (4.6 × 250 mm and 5 m particle size) eluted with isocratic system; mobile 
phase composed of 93% acetonitrile-sodium octyl sulphate (10 mM), and 7% of the solution composed of 
triethanolamine and azide (0.2%: 0.001%, v/v) (pH 2.5) adjusted with orthophosphoric acid; flow rate of 1 
ml/min. The tests were run at 245 nm wavelength that was previously identified as DEHP standard in UV-
VIS spectrophotometer NanoDrop
TM
, Model ND-1000. The retention times were 8 min. Figure 2 presents the 













Figura 2: Chromatogram showing the detection or DEPH at a retention time of 8 min. 
The calibration curve for the DEHP quantification was constructed using seven samples of plasma 
from the same healthy volunteers, in which were added 0.000197 µg/µl, 0.000394 µg/µl, 0.000788 µg/µl, 
0.001182 µg/µl, 0.001576 µg/µl, 0.00394 µg/µl and 0.00995 µg/µl, respectively, of the DEHP standard 
solution diluted with the mobile phase. The DEHP standard solution was purchased from a commercial 
source (Selectophor
TM
, Sigma-Aldrich). The calibration curves provided a correlation coefficient (r
2
) always 
superior to 0.99, ensuring that the areas under the curves were directly proportional to the analyte concentra-
tion.  
The plasma samples (two from each patient volunteer) were defrosted until they reached the 
temperature of 20 °C to perform the HPLC analysis. The proteins of 250 µL of plasma were precipitated with 
a solution containing 750 µl of acetonitrile and 250 µl of saturated (NH4)2SO4. After mixing in a vortex, the 
suspensions were centrifuged at 11.336 xg for 20 min at 4 
o
C. The supernatant was collected and filtered us-
ing a 0.22 µm filter (Minisart filter, Sigma-Aldrich). One hundred microliters were eluted with the mobile 
phase and injected into the HPLC equipment. 
The analysis was performed in six days, and a standard curve was generated in each day where a line-
ar regression was applied. The concentration of DEHP was determined by replacing the independent variable 
“x” in the linear equation by the area under the peak of detection. Figure 3 illustrates the peak detection of 









Figura 3: Chromatogram showing the detection of DEPH in the patient’s blood (A) and the DEPH standard (B) at a 
retention time of 8 min. 
The non-parametric Kruskal-Wallis test was applied to evaluate if there were differences between the 
mass of DEHP released per session for different patients, at the 0.05 significance level. The study was per-
formed according to the national and international standards of ethics in research involving human beings 
(Ethics Committee Protocol PUCPR n. 5802). 
3. RESULTS 
Table 2 shows the results of the linear regression of the curves generated during the HPLC analysis for the 
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Volunteer / session 
Area under the peak 
(x) 
1 y=3.10-8x – 4.10-5 0.9974 
P4 / 1 initial 
P4 /1 final 
P4 / 2 initial 
P4 / 2 final 
P4 / 3 initial 
P4 / 3 final 
P5 / 1 initial 
P5 / 1 final 
P5 / 2 initial 











2 y=2.10-8x + 2.10-5 0.9990 
P5 / 3 initial 
P5 / 3 final 
3,803.2 
23,950.4 
3 y=2.10-8x + 6.10-6 0.9913 
P1 / 1 initial 
P1 / 1 final 
P1 / 2 initial 
P1 / 2 final 
P1 / 3 initial 







4 y= 3.10-8x+ 8.10-5 0.9954 
P2 / 1 initial 
P2 / 1 final 
P2 / 2 initial 
P2 / 2 final 
P2 / 3 initial 







5 y= 3.10-8 x + 2.10-5 0.9989 
P3 / 1 initial 
P3 / 1 final 
P3 / 2 initial 
P3 / 2 final  
P3 / 3 initial 














P = volunteer patient; V = healthy volunteer. 
The coefficient of determination (r
2
) of the linear regression of each calibration curve was determined 
to verify its reliability. Among the coefficients of determination, the lowest value was 0.9913 being, therefore, 
by the ANVISA and the National Institute of Metrology (INMETRO) requirements (above 0.90) [22]. Table 
3 presents the mass of DEHP determined using the linear regression equations showed in Table 2. 
The VC shows low homogeneity of data meaning that the cumulative DEHP is not only related to the 
extracorporeal circuit and the conditions of the procedure and can be attributed to the metabolic condition of 
the patient. However, in all cases, it was found higher values of DEHP in the blood near to the end of session 
compared to the beginning. 
The amount of DEHP released depends on the blood flow and on the exposure time of the blood to the 
PVC circuit [23] [24]. Then the DEHP accumulated per patient per session (ΔDEHP) was multiplied by the 
blood flow and by the dialysis period (240 min). The results in mg (MDEHP) were used to calculate the av-
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Table 3: The concentration of DEHP in the blood of the volunteer patients determined using the data from Table 2. 
Patient 
/session 
Concentration of DEHP 
(µg/ml) 15 min after the 
session has started 
Concentration of DEHP 
(µg/ml) 15 min before the 
session has finished 
DEHP accumulated 
per patient, DEHPm 




P1 / 1 
P1 / 2 








P2 / 1 
P2 / 2 








P3 / 1 
P3 / 2 








P4 / 1 
P4 / 2 








P5 / 1 
P5 / 2 








Samples with * indicate concentration below the limit of quantification (< 0.197 µg/ml); SD = Standard 
Desviation; VC = Variation Coeficient. 
 
Applying the non-parametric Kruskal-Wallis test to the MDEPH values, it is concluded that there is 
not enough evidence to claim that the medians are different from each other, at the 0.05 significance level 
inferring, therefore, that at least one pair of medians is unequal. However, it is possible to compare the pa-
tients each other and to compare the patients with the healthy volunteers. 











MDEHPM (mg) ± 
SD 
P1 / 1 
P1 / 2 












P2 / 1 
P2 / 2 












P3 / 1 
P3 / 2 












P4 / 1 
P4 / 2 












P5 / 1 
P5 / 2 













In Table 4, the MDEHP and the MDEHPM were not determined for the samples indicated in Table 3 
having concentrations below the limit of quantification (0.197 µg/ml). However, the DEHP (µg/ml) and the 
DEHP x flow (µg/min) can be used to conclude about the DEHP released in the blood of the patients. 
Table 5 shows the body weight of each patient and the average mass of DEHP released per kg of body 
weight (MDEHPMK). Table 6 displays the mass of DEHP detected in the blood of the healthy volunteers per 
kg of body weight for comparison with the volunteer patients. 
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P2 11.32±8.45 60.0±0.05 0.19±0.14 
P3 1,80±0,00 71.5±0.05 0.07±0.05 
P4 27.78±23.81 70.0±0.05 0.39±0.34 
P5 19.43±17.24 75.5±0.05 0.26±0.23 






Body weight  
(kg) 
DEHPM (µg/kg) 
V1 0.035 0.35 60.20±0.05 0.006±0,001 
V2 0.002 0.02 54.50±0.05 0.000±0.001 
V3 0.012 0.12 56.40±0.05 0.002±0.001 
 
From Table 5 and Table 6 one can see that the mass of DEHP in the blood of the healthy volunteers is 
in the order of µg/kg while for the patients is in the order of mg/kg.  The average DEHP for the healthy vol-
unteer was 0.003±0.002 µg/kg, and for patients volunteer was 0.19±0.16 mg/kg, much higher than the first 
one. Although the reduced number of volunteer prevents the validation of the method, it can be used to verify 
its feasibility as well as the right procedure to prepare samples from the blood to analyze in HPLC equipment. 
4. DISCUSSION 
Analyzing the hemodialysis sessions 1, 2 and 3 of each patient one can see the change in the average amount 
of DEHP released, also observed in the literature that records values between 44.3 mg and 197.1 mg in a sin-
gle dialysis session [23] [24]. The variation observed can be linked to the lipophilic nature of the blood of 
each patient, the time of collection, or to his hepatic function because DEHP is metabolized in the liver [12] 
[26]. 
Regarding the reuse of the extracorporeal circuit, it was expected that the amount of DEHP released 
increased with the number of reuses. Because the DEHP is not strongly bonded to the PVC [18] [27], it can 
easily release into the blood, and the more degraded is the polymer more plasticizer is released. However, the 
DEHP of the P3 who reused the circuit thirteen times was lower than that of the P4 with four reuse. One 
possible reason is the heterogeneity of the polymeric material. As the plasticizer is added to the polymeric 
raw material before or during the extrusion process for manufacturing the circuit, an inhomogeneous mixture 
of DEHP plasticizer in the PVC may occur creating sites with high concentrations of the plasticizer [28]. 
These sites, when in contact with the blood can release a high amount of DEHP [29] instantly that may ex-
plain the discrepancy between values in the same patient.  
The P5 started the sessions with high concentrations of DEHP in the blood. The circuit was reused fif-
teen times in this patient, and it was, therefore, in a high level of degradation, and even though had received 
the higher amount of heparin, the DEHPm in the P5 blood was the highest (0.232±0.205 mg/kg). Heparin is 
hepatic lipase activator [30] and, consequently, the patients that continuously receive it have an increasing 
conversion rate of DEHP into its metabolic, resulting in a reduced amount of DEHP detected in the plasma. 
Therefore, even taking 8,000 UI of heparin, the patient 5 did not metabolize the DEHP as expected, because 
having constant contact with the contaminant the body's ability to metabolize it can be affected [26]. 
The heparin effect can also be seen in the P2 that, having the same flow of the patients P1 and P3, pre-
sented higher concentration of DEHP (0.19±0.14 mg/kg), especially when compared to P3 (0.07±0.05 
mg/kg) who had taken 6,000 UI of heparin and thirteen reuses.  
Analyzing the blood flow, the patients P4 and P5, which had a higher flow than the other, had a higher 
value of DEHP released despite receiving a greater amount of heparin. The higher doses of heparin are 
justified by the local shear stresses between the blood and the PVC surface that activate the platelets and in-
crease the probability of thrombus formation. In the extracorporeal circuits, the tubes with an average diame-
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ter of 3 mm suffer shear stresses up to 63 dynes/cm
2
. The stresses that activate the platelets occur between 60 
and 80 dynes/cm
2 
[31]. The higher flow rate also makes the volume of blood transit more times in the circuit 
increasing the amount of DEHP released.  
Data from Table 6 show that, although DEHP is not absent in the blood of the healthy volunteers due 
to their exposure to this compound normally found in the environment, the concentrations are very low com-
pared to those in the blood of the volunteer patients. For the healthy volunteers, it was found an average val-
ue of 0.003±0.002 µg/kg, and a much higher value (0.19±0.21 mg/kg) was found in the blood of the volun-
teer patients.  
A higher value of the concentration of DEHP in the blood of healthy volunteers (0.62±0.12 µg/ml) 
was detected in the study conducted by FAOUZI et al. [20] The lower average concentration of 0.016±0.017 
µg/ml found in the present study can be explained by the fact that it strongly depends on the environment 
where the volunteer is in contact daily. Studies that monitored DEHP in indoor air reported about 
0.11 μg/m
3
 in Japan and about 0.09 μg/m
3
 in the USA [32]. 
Considering the P2 with an average of 11.32±8.45 mg of DEHP in three sessions, the amount of 
DEHP in a year of 52 weeks would be about 0.59 g. This value is still very low according to the literature. 
FAOUZI et al. [20], reported the amount of 11,74 g, considering sessions of four hours, three times a week, 
and using HPLC as detection instrument. Also, the same authors found the maximum concentration of DEHP 
in the blood of 21 hemodialysis patients of 4.2 μg/ml against 0.523 µg/ml found in this study.  
Either way, based on the daily limit of DEHP defined by the RDC 35, 2014 ANVISA as 0.025 mg/kg 
of body mass, all patients volunteer had average values substantially higher than the maximum set by the 
ANVISA. 
5. CONCLUSIONS 
Despite the limited number of patients, the aim of this study was to demonstrate the feasibility of the HPLC 
to quantify the DEHP in the blood of hemodialyzed patients presenting the steps to prepare the plasma sam-
ples and to handle the results from the HPLC. The findings indicate that patients undergoing hemodialysis 
using extracorporeal circuit manufactured in PVC are exposed to high doses of DEHP.  
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